Cubist Pharmaceuticals (CBST) 96.31 $CBST
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST
PR Newswire - Fri Dec 12, 7:30PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company"
(Nasdaq: CBST) for potential breaches of fiduciary duties in connection with the sale of the Company to Merck & Co., Inc. ("Merck" (NYSE: MRK) for approximately $9.5 billion in an all-cash transaction. The Company's stockholders will receive $102 for each share of Cubist common stock they own.
CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Fri Dec 12, 4:07PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company" (Nasdaq: CBST) relating to the proposed buyout of the Company by Merck & Co., Inc. ("Merck" .
CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
Seeking Alpha's Biotech Weekly: Spark Flies For Pfizer, Sovaldi V. Septa, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 12, 2:29PM CST
Welcome to a new Seeking Alpha feature, the SA Biotech Weekly. Every Friday, we will highlight the editors' picks of the past week's most interesting and impactful pieces of Seeking Alpha analysis, as well as a list of the top Breaking News stories...
JNJ: 104.43 (-2.29), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.
Business Wire - Fri Dec 12, 9:19AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. (NasdaqGS: CBST) ("Cubist" in connection with the sale of the Company to Merck & Co.
CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Thu Dec 11, 1:22PM CST
Rigrodsky & Long, P.A.:
CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
Lifshitz & Miller Law Firm Announces Investigation of Actuate Corporation, Albany Molecular Research Inc., Conn's, Inc., Cubist Pharmaceuticals, Inc., Hawaiian Electric Industries, Inc., and Heritage Financial Group, Inc.
PR Newswire - Thu Dec 11, 11:45AM CST
Actuate Corporation
BIRT: 6.54 (-0.01), CBSTZ: 0.04 (-0.01), HE: 32.98 (-0.20), CBST: 96.31 (+0.04), CONN: 17.44 (+0.35), AMRI: 15.84 (-0.14), HBOS: 25.23 (-0.17)
Update: Cubist Pharmaceuticals Is Acquired By Merck, Gains Remain For Investors
David Zanoni - at Seeking Alpha - Wed Dec 10, 11:31PM CST
CBST: 96.31 (+0.04), MRK: 57.72 (-1.62), HSP: 60.33 (-1.75)
Merck-Cubist Deal On Despite Patent Setback, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 3:30PM CST
Merck (MRK) intends to go ahead with the Cubist acquisition despite the recent unfavorable court ruling regarding Cubicin.
CBST: 96.31 (+0.04), MRK: 57.72 (-1.62), TEVA: 55.92 (-0.92), HSP: 60.33 (-1.75)
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), ARRY: 4.86 (-0.04)
CBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co.
Business Wire - Wed Dec 10, 11:51AM CST
Levi & Korsinsky is investigating the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist Pharmaceuticals" or "the Company" (NasdaqGS:CBST) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Merck & Co.
CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
Cubist Pharmaceuticals Has Returned 43.8% Since SmarTrend Recommendation (CBST)
Comtex SmarTrend(R) - Wed Dec 10, 11:00AM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 2 months, Cubist Pharmaceuticals has returned 43.81% as of today's recent price of $96.00.
CBST: 96.31 (+0.04)
Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 111.34 (-1.90), ENDP: 68.77 (-2.45), BDX: 136.99 (-1.03), MDT: 72.52 (-1.25), COV: 100.49 (-1.36), ITMN: 73.89 (-0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), JNJ: 104.43 (-2.29), CBST: 96.31 (+0.04), CFN: 58.86 (-0.14), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), IDIX: 24.50 (+0.05), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)
Downgrade Alert for Cubist Pharmaceuticals (CBST)
Comtex SmarTrend(R) - Wed Dec 10, 6:52AM CST
Cubist Pharmaceuticals (NASDAQ:CBST) was downgraded from Outperform to Perform at Oppenheimer today. The stock closed yesterday at $95.83 on volume of 25.3 million shares, above average daily volume of 554,000. Cubist Pharmaceuticals share prices have moved between a 52-week high of $101.03 and a 52-week low of $58.50 and closed yesterday at 64% above that low price at $95.83 per share. The 200-day and 50-day moving averages have moved 0.25% higher and 2.07% higher over the past week, respectively.
CBST: 96.31 (+0.04)
Cramer's Mad Money - Game Over For GameStop? (12/9/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 10, 3:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday December 9. GameStop (NYSE: GME ) Is A Value Trap. Other stock mentioned: Best Buy (NYSE: BBY ), Electronic Arts (NASDAQ: EA ) GameStop ( GME ) should be...
LMT: 185.18 (-4.07), EA: 44.90 (-0.22), GME: 32.30 (-1.61), NUE: 51.88 (-1.09), UTX: 112.15 (-1.89), BBY: 36.85 (+0.22), SLB: 80.00 (-3.01), NFLX: 334.48 (-0.15), SAVE: 68.12 (-0.88), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62), CONN: 17.44 (+0.35), MCD: 90.62 (-0.35), AYR: 20.00 (-1.15), VZ: 45.58 (-0.78), NRG: 26.66 (-0.26)
Acquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests
PR Newswire - Tue Dec 09, 8:31PM CST
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) by Merck & Co., Inc. (NYSE: MRK). On December 8, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Merck will acquire Cubist Pharmaceuticals. Under the terms of the agreement, Cubist Pharmaceuticals shareholders will receive $102 for each share of Cubist Pharmaceuticals common stock.
CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
Merck-Cubist deal going ahead
at Investor's Business Daily - Tue Dec 09, 5:42PM CST
The $9.5 bil acquisition is advancing, even though Cubist Pharma's (CBST) lead drug may face generic competition sooner than expected. The companies announced the deal Mon., hours before a federal judge in Del. ruled as invalid 4 of 5 Cubist patents...
CBST: 96.31 (+0.04), MRK: 57.72 (-1.62), HSP: 60.33 (-1.75)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
DRIV: 16.89 (+0.31), CBST: 96.31 (+0.04), OVLY: 10.22 (-0.03), IBKC: 62.12 (-1.08), CONN: 17.44 (+0.35), GPIC: 8.22 (+0.01), CLDN: 17.25 (+0.75), LPTN: 2.85 (+0.05), CNVR: 34.44 (-0.24), WILC: 7.01 (-0.10)
Most active Nasdaq-traded stocks
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.47 (+0.37), CBST: 96.31 (+0.04), FB: 77.83 (+0.10), MSFT: 46.95 (-0.22), INTC: 36.22 (-0.48), AAPL: 109.73 (-1.89), CSCO: 26.85 (-0.14)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OFED: 20.00 (+0.94), EFOI: 5.70 (+0.21), CBST: 96.31 (+0.04), AKAO: 11.91 (-0.31), CEMP: 19.00 (+0.47), PDCE: 33.13 (-0.89), MTEX: 28.10 (-1.00), OTIC: 36.72 (+2.60)
Will Merck's Acquisition Of Cubist Add Shareholder Value?
Raman Minhas - at Seeking Alpha - Tue Dec 09, 3:45PM CST
Merck To Buy Antibiotics Maker For $8.4 Billion - Deal rationale for Merck (NYSE: MRK ) to buy Cubist (NASDAQ: CBST ) is to build up antibiotics and hospital acute care portfolio as one of 4 core areas going forwards (others are diabetes, cancer and...
CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST
PR Newswire - Fri Dec 12, 7:30PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company"
(Nasdaq: CBST) for potential breaches of fiduciary duties in connection with the sale of the Company to Merck & Co., Inc. ("Merck" (NYSE: MRK) for approximately $9.5 billion in an all-cash transaction. The Company's stockholders will receive $102 for each share of Cubist common stock they own. CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Fri Dec 12, 4:07PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist" or the "Company"
(Nasdaq: CBST) relating to the proposed buyout of the Company by Merck & Co., Inc. ("Merck" . CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
Seeking Alpha's Biotech Weekly: Spark Flies For Pfizer, Sovaldi V. Septa, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 12, 2:29PM CST
Welcome to a new Seeking Alpha feature, the SA Biotech Weekly. Every Friday, we will highlight the editors' picks of the past week's most interesting and impactful pieces of Seeking Alpha analysis, as well as a list of the top Breaking News stories...
JNJ: 104.43 (-2.29), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.
Business Wire - Fri Dec 12, 9:19AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. (NasdaqGS: CBST) ("Cubist"
in connection with the sale of the Company to Merck & Co. CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Thu Dec 11, 1:22PM CST
Rigrodsky & Long, P.A.:
CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
Lifshitz & Miller Law Firm Announces Investigation of Actuate Corporation, Albany Molecular Research Inc., Conn's, Inc., Cubist Pharmaceuticals, Inc., Hawaiian Electric Industries, Inc., and Heritage Financial Group, Inc.
PR Newswire - Thu Dec 11, 11:45AM CST
Actuate Corporation
BIRT: 6.54 (-0.01), CBSTZ: 0.04 (-0.01), HE: 32.98 (-0.20), CBST: 96.31 (+0.04), CONN: 17.44 (+0.35), AMRI: 15.84 (-0.14), HBOS: 25.23 (-0.17)
Update: Cubist Pharmaceuticals Is Acquired By Merck, Gains Remain For Investors
David Zanoni - at Seeking Alpha - Wed Dec 10, 11:31PM CST
CBST: 96.31 (+0.04), MRK: 57.72 (-1.62), HSP: 60.33 (-1.75)
Merck-Cubist Deal On Despite Patent Setback, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 3:30PM CST
Merck (MRK) intends to go ahead with the Cubist acquisition despite the recent unfavorable court ruling regarding Cubicin.
CBST: 96.31 (+0.04), MRK: 57.72 (-1.62), TEVA: 55.92 (-0.92), HSP: 60.33 (-1.75)
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), ARRY: 4.86 (-0.04)
CBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co.
Business Wire - Wed Dec 10, 11:51AM CST
Levi & Korsinsky is investigating the Board of Directors of Cubist Pharmaceuticals, Inc. ("Cubist Pharmaceuticals" or "the Company"
(NasdaqGS:CBST) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Merck & Co. CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
Cubist Pharmaceuticals Has Returned 43.8% Since SmarTrend Recommendation (CBST)
Comtex SmarTrend(R) - Wed Dec 10, 11:00AM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 2 months, Cubist Pharmaceuticals has returned 43.81% as of today's recent price of $96.00.
CBST: 96.31 (+0.04)
Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 111.34 (-1.90), ENDP: 68.77 (-2.45), BDX: 136.99 (-1.03), MDT: 72.52 (-1.25), COV: 100.49 (-1.36), ITMN: 73.89 (-0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), JNJ: 104.43 (-2.29), CBST: 96.31 (+0.04), CFN: 58.86 (-0.14), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), IDIX: 24.50 (+0.05), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)
Downgrade Alert for Cubist Pharmaceuticals (CBST)
Comtex SmarTrend(R) - Wed Dec 10, 6:52AM CST
Cubist Pharmaceuticals (NASDAQ:CBST) was downgraded from Outperform to Perform at Oppenheimer today. The stock closed yesterday at $95.83 on volume of 25.3 million shares, above average daily volume of 554,000. Cubist Pharmaceuticals share prices have moved between a 52-week high of $101.03 and a 52-week low of $58.50 and closed yesterday at 64% above that low price at $95.83 per share. The 200-day and 50-day moving averages have moved 0.25% higher and 2.07% higher over the past week, respectively.
CBST: 96.31 (+0.04)
Cramer's Mad Money - Game Over For GameStop? (12/9/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 10, 3:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday December 9. GameStop (NYSE: GME ) Is A Value Trap. Other stock mentioned: Best Buy (NYSE: BBY ), Electronic Arts (NASDAQ: EA ) GameStop ( GME ) should be...
LMT: 185.18 (-4.07), EA: 44.90 (-0.22), GME: 32.30 (-1.61), NUE: 51.88 (-1.09), UTX: 112.15 (-1.89), BBY: 36.85 (+0.22), SLB: 80.00 (-3.01), NFLX: 334.48 (-0.15), SAVE: 68.12 (-0.88), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62), CONN: 17.44 (+0.35), MCD: 90.62 (-0.35), AYR: 20.00 (-1.15), VZ: 45.58 (-0.78), NRG: 26.66 (-0.26)
Acquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests
PR Newswire - Tue Dec 09, 8:31PM CST
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) by Merck & Co., Inc. (NYSE: MRK). On December 8, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Merck will acquire Cubist Pharmaceuticals. Under the terms of the agreement, Cubist Pharmaceuticals shareholders will receive $102 for each share of Cubist Pharmaceuticals common stock.
CBSTZ: 0.04 (-0.01), CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
Merck-Cubist deal going ahead
at Investor's Business Daily - Tue Dec 09, 5:42PM CST
The $9.5 bil acquisition is advancing, even though Cubist Pharma's (CBST) lead drug may face generic competition sooner than expected. The companies announced the deal Mon., hours before a federal judge in Del. ruled as invalid 4 of 5 Cubist patents...
CBST: 96.31 (+0.04), MRK: 57.72 (-1.62), HSP: 60.33 (-1.75)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
DRIV: 16.89 (+0.31), CBST: 96.31 (+0.04), OVLY: 10.22 (-0.03), IBKC: 62.12 (-1.08), CONN: 17.44 (+0.35), GPIC: 8.22 (+0.01), CLDN: 17.25 (+0.75), LPTN: 2.85 (+0.05), CNVR: 34.44 (-0.24), WILC: 7.01 (-0.10)
Most active Nasdaq-traded stocks
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.47 (+0.37), CBST: 96.31 (+0.04), FB: 77.83 (+0.10), MSFT: 46.95 (-0.22), INTC: 36.22 (-0.48), AAPL: 109.73 (-1.89), CSCO: 26.85 (-0.14)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OFED: 20.00 (+0.94), EFOI: 5.70 (+0.21), CBST: 96.31 (+0.04), AKAO: 11.91 (-0.31), CEMP: 19.00 (+0.47), PDCE: 33.13 (-0.89), MTEX: 28.10 (-1.00), OTIC: 36.72 (+2.60)
Will Merck's Acquisition Of Cubist Add Shareholder Value?
Raman Minhas - at Seeking Alpha - Tue Dec 09, 3:45PM CST
Merck To Buy Antibiotics Maker For $8.4 Billion - Deal rationale for Merck (NYSE: MRK ) to buy Cubist (NASDAQ: CBST ) is to build up antibiotics and hospital acute care portfolio as one of 4 core areas going forwards (others are diabetes, cancer and...
CBST: 96.31 (+0.04), MRK: 57.72 (-1.62)
